Phytocannabinoids reduce inflammation of primed macrophages and enteric glial cells Critical review of the effect of phytocannabinoids on gut immune cells

In vitro study analyzed the putative-anti-inflammatory effect of nine-selected pure cannabinoids on enteric glial cells (EGC’s) triggered to undergo inflammation with lipopolysaccharide (LPS) . Our results demonstrate that THC at the lower concentrations tested exerted the most effective anti- inflammatory effect in EGC’s compared to other phytocannabinoids tested herein. We then performed RNA-seq analysis of EGC’s exposed to LPS in the presence or absence of THC or THC-COOH. Transcriptomic analysis of these EGC’s revealed 23 differentially expressed genes (DEG) compared to treatment with only LPS. Pretreatment with THC resulted in 26 DEG and THC-COOH 25 DEG. To evaluate biological pathways affected by the different phytocannabinoid treatments we used the Ingenuity platform. We show that THC treatment but not THC-COOH affected本体外实验（in vitro）探究了9种筛选得到的纯大麻素类化合物对经脂多糖（lipopolysaccharide, LPS）诱导炎症的肠胶质细胞（enteric glial cells, EGCs）的潜在抗炎效应。研究结果表明，与本实验中测试的其他植物大麻素相比，低浓度受试的四氢大麻酚（THC）在肠胶质细胞中展现出最为显著的抗炎效果。随后，我们对暴露于脂多糖环境、分别添加或不添加四氢大麻酚（THC）及其代谢产物四氢大麻酚羧酸（THC-COOH）的肠胶质细胞开展了RNA测序（RNA-seq）分析。对该批肠胶质细胞的转录组学分析显示，与仅经脂多糖处理的对照组相比，脂多糖单独处理组存在23个差异表达基因（differentially expressed genes, DEGs）；经四氢大麻酚预处理的实验组存在26个差异表达基因，而经四氢大麻酚羧酸预处理的实验组存在25个差异表达基因。为评估不同植物大麻素处理所影响的生物学通路，我们采用了Ingenuity通路分析平台。我们证实，仅四氢大麻酚处理可影响相关生物学通路，而四氢大麻酚羧酸处理则未产生此效应。